Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "REACH"

909 News Found

Biocon Biologics collaborates with National Cancer Society Malaysia
Healthcare | June 24, 2025

Biocon Biologics collaborates with National Cancer Society Malaysia

The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints


Sigachi Industries gets ToR approval for API and specialty chemicals manufacturing facility in Andhra Pradesh
News | June 13, 2025

Sigachi Industries gets ToR approval for API and specialty chemicals manufacturing facility in Andhra Pradesh

The project will be instrumental in enhancing the company's API manufacturing capacity and global reach


Aayush Wellness to form subsidiary in Singapore to drive Southeast Asia expansion
News | June 12, 2025

Aayush Wellness to form subsidiary in Singapore to drive Southeast Asia expansion

This strategic expansion marks a significant step in the company's global growth strategy


Lubrizol's polymer excipient Apisolex featured in Phase I candidate
News | June 11, 2025

Lubrizol's polymer excipient Apisolex featured in Phase I candidate

The use of Apisolex polymer excipient has been proven to increase the solubility of certain APIs by as much as 50,000-fold


Brenntag Specialties acquires mcePharma to cater growing demand in Biopharma market
Supply Chain | June 11, 2025

Brenntag Specialties acquires mcePharma to cater growing demand in Biopharma market

The acquisition sets up the foundation for a central hub of GMP value-added services and greater access to new customers in the rapidly growing Biopharma market


Health Minister Nadda delivers keynote address at FSSAI’s World Food Safety Day 2025
Policy | June 09, 2025

Health Minister Nadda delivers keynote address at FSSAI’s World Food Safety Day 2025

Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme


AstraZeneca’s fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia
News | June 07, 2025

AstraZeneca’s fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia

AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations